Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
- Associated Therapies
- -
Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction
- Conditions
- Interventions
- First Posted Date
- 2017-05-24
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 34
- Registration Number
- NCT03165292
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, Val De Marne, France
🇦🇹St. Anna Kinderspital GmbH, Vienna, Austria
🇮🇹Fondazione IRCCS Istituto nazionaleTumori, Milano, Italy
Chronic Convection Enhanced Delivery of Topotecan
- Conditions
- Interventions
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Jeffrey N. Bruce
- Target Recruit Count
- 5
- Registration Number
- NCT03154996
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-02-09
- Target Recruit Count
- 65
- Registration Number
- NCT03107988
- Locations
- 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇺🇸Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2020-12-09
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 483
- Registration Number
- NCT03098030
- Locations
- 🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States
🇺🇸Hartford Hospital, Hartford, Connecticut, United States
🇭🇺Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Semmelweis Tagkórház, Tüdőgyógyászati Osztály, Miskolc, Hungary
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Ipsen
- Target Recruit Count
- 491
- Registration Number
- NCT03088813
- Locations
- 🇺🇸
Florida Cancer Specialists (South Region), Fort Myers, Florida, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸North Shore Hematology Oncology Associates, PC, East Setauket, New York, United States
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-10
- Target Recruit Count
- 73
- Registration Number
- NCT03059667
- Locations
- 🇫🇷
Mulhouse - CH, Mulhouse, France
🇫🇷Centre Antoine Lacassagne, Nice, France
🇫🇷Annemasse - CH, Ambilly, France
Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 444
- Registration Number
- NCT03061812
- Locations
- 🇺🇸
Georgia Cancer Center /ID# 160206, Atlanta, Georgia, United States
🇺🇸Cedars-Sinai Medical Center /ID# 157102, Beverly Hills, California, United States
🇺🇸Mitchell Cancer Institute /ID# 158151, Mobile, Alabama, United States
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2016-12-02
- Target Recruit Count
- 60
- Registration Number
- NCT02980809
Pembrolizumab vs Topotecan in Patients With Small Cell Lung Cancer
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2023-02-15
- Lead Sponsor
- Alliance Foundation Trials, LLC.
- Target Recruit Count
- 9
- Registration Number
- NCT02963090
- Locations
- 🇺🇸
Metro MN Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients
- Conditions
- Interventions
- First Posted Date
- 2016-09-16
- Last Posted Date
- 2021-08-25
- Target Recruit Count
- 242
- Registration Number
- NCT02903004
- Locations
- 🇮🇹
Domenica Lorusso, Rome, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.